Generic Medicine Info
Indications and Dosage
Chronic idiopathic constipation
Adult: 2 mg once daily.
Elderly: Initially, 1 mg once daily, may increase to 2 mg once daily if necessary.
Renal Impairment
Severe (GFR <30 mL/min/1.73 m2): 1 mg once daily. Patient on dialysis: Contraindicated.
Hepatic Impairment
Severe (Child-Pugh Class C): Initially, 1 mg once daily, may increase to 2 mg once daily if necessary.
May be taken with or without food.
Intestinal obstruction or perforation, obstructive ileus, active severe inflammatory bowel conditions (e.g. Crohn’s disease, toxic megacolon/megarectum, and ulcerative colitis). Renal impairment requiring dialysis. Pregnancy and lactation.
Special Precautions
Patient w/ history of arrhythmias or ischaemic CV disease, severe and unstable concomitant disease (e.g. cancer, AIDS, neurological or psychiatric, pulmonary, IDDM or other endocrine disroders). Severe hepatic (Child-Pugh Class C) and renal (GFR <30 mL/min/1.73 m2) impairment. Elderly.
Adverse Reactions
Nervous: Headache, dizziness, fatigue, malaise, tremors.
CV: Palpitations.
GI: Nausea, abdominal pain and distention, diarrhoea, vomiting, flatulence, dyspepsia, anorexia, rectal bleeding, gastroenteritis.
Genitourinary: Polyuria, pollakiuria.
Musculoskeletal: Muscle spasm.
Others: Fever.
Patient Counseling Information
This drug may cause dizziness and fatigue, if affected, do not drive or operate machinery.
Monitoring Parameters
Monitor bowel movement frequency.
Drug Interactions
May decrease serum concentration of contraceptives (i.e. oestrogens, progestins). May enhance adverse effect of levosulpiride. Increased serum concentration w/ P-glycoprotein/ABCB1 inhibitors. Reduced effect w/ atropine-like substance.
Mechanism of Action: Prucalopride is a selective 5-HT4 receptor agonist w/ prokinetic effect. It stimulates peristaltic reflex, intestinal secretions, and GI motility.
Absorption: Rapidly absorbed from the GI tract. Absolute bioavailability: >90%. Time to peak plasma concentration: 2-3 hr.
Distribution: Extensively distributed; enters breast milk. Volume of distribution: 567 L. Plasma protein binding: Approx 30%.
Metabolism: Metabolised slowly in the liver.
Excretion: Via urine (approx 60-65% as unchanged drug); faeces (approx 5% as unchanged drug). Terminal elimination half-life: Approx 24 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Prucalopride, CID=3052762, (accessed on Jan. 23, 2020)

Store between 15-30°C.
MIMS Class
GIT Regulators, Antiflatulents & Anti-Inflammatories
ATC Classification
A06AX05 - prucalopride ; Belongs to the class of other laxatives.
Anon. Prucalopride. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 03/04/2017.

Buckingham R (ed). Prucalopride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 03/04/2017.

Joint Formulary Committee. Prucalopride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 03/04/2017.

Disclaimer: This information is independently developed by MIMS based on Prucalopride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2023 MIMS. All rights reserved. Powered by
  • Resolor
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in